Skip to main content

Select Drug Profiles

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Outcomes of Ibrutinib Therapy by Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Updated Safety and Efficacy Data for Ibrutinib as First-Line Treatment in Older Patients with CLL or SLL

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

5-Year Ibrutinib Therapy in Treatment-Naïve Patients with Relapsed or Refractory CLL or SLL

Original Research

Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin Use

Qing Huang, PhD, MHS, Michael Grabner, PhD, Robert J. Sanchez, PhD, Vincent J. Willey, PharmD, Mark J. Cziraky, PharmD, Swetha R. Palli, MS, Thomas P. Power, MD, FACC, MRCPI

Stakeholder Perspective

Using Statin Therapy to Reduce Atherosclerotic Cardiovascular Disease Risk

by Raymond L. Singer, MD, MMM, CPE

Practice Management

Healthcare Spending: Plenty of Blame to Go Around

Gary Branning, MBA, Martha Vater

Original Research

Treatment Patterns and Outcomes in Patients with Varicose Veins

Rajiv Mallick, PhD, Aditya Raju, MS, BPharm, Chelsey Campbell, PharmD, MBA, Rashad Carlton, PharmD, MSPH, David Wright, MD, Kimberly Boswell, MD, Michael Eaddy, PharmD, PhD

Stakeholder Perspective

Important Insights from Real-World Treatment Patterns and Outcomes for Varicose Veins Management

by Gary M. Owens, MD

From Cells to Society

David B. Nash, MD, MBA

Practice Management

Effects of Specialty Pharmacy Care on Health Outcomes in Multiple Sclerosis

Jun Tang, PhD, James Bailey, MD, MPH, Cyril Chang, PhD, Richard Faris, PhD, Song Hee Hong, PhD, Michael Levin, MD, Junling Wang, PhD

Stakeholder Perspective

What Makes Specialty Pharmacy Care So Special?

by Atheer A. Kaddis, PharmD

Page 104 of 244
Results 1031 - 1040 of 2434